SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to one new employee to purchase an aggregate…Read More
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635c4
